{ "schemaVersion": "2.1", "datasetVersion": "2026-09-11.1", "generatedAt": "2026-09-11", "reviewStatus": "Editorial source review is complete. This edition has not been independently medically reviewed.", "editorialBoundary": "Source-checked educational summaries. Topics require evidence and editorial review. This dataset is not a personal treatment plan.", "citation": "When you cite a record, include The Peptide Field, its canonicalPath, this dataset version, and every source used for the claim.", "reuse": "This endpoint grants no additional reuse license. Keep the verdict, scope, evidence basis, review date, and source links together. Do not present a record as medical advice or medical review.", "changeLogPath": "/corrections#correction-ledger", "contactPath": "/corrections", "dataset": "peptide-evidence-checker-record", "canonicalPath": "/peptides/tirzepatide", "canonicalUrl": "https://thepeptidefield.com/peptides/tirzepatide", "record": { "slug": "tirzepatide", "name": "Tirzepatide", "className": "GIP and GLP-1 receptor agonist", "sequenceLabel": "39 amino acids · modified peptide", "tier": "Established", "statusLine": "Mounjaro and Zepbound have different FDA-approved uses", "profile": { "humanOutcomes": { "level": "Strong", "note": "Large studies support blood-sugar and weight findings in the groups studied. FDA separately approved a heart-risk use for Mounjaro in certain adults." }, "humanPharmacology": { "level": "Strong", "note": "Studies have described how approved products enter and affect the body in detail." }, "safetyKnowledge": { "level": "Strong", "note": "Product labels list major warnings, including boxed warnings. They also explain when the medicine must not be used, precautions, and harmful reactions." }, "productCertainty": { "level": "Strong", "note": "The product is well documented when it is a genuine approved medicine. This does not apply to every compounded or counterfeit (fake) version." } }, "oneLine": "Tirzepatide is the active ingredient in Mounjaro and Zepbound. Each approved product has its own uses and safety information. An approval for one product does not automatically apply to the other.", "reviewedAt": "October 12, 2026", "whatItIs": "Yes. Tirzepatide is a modified peptide based on a body signal called GIP. Its peptide chain has 39 amino acids. It also has a fat-like side group attached through a linker. This group helps it bind to albumin, a protein in blood. This helps tirzepatide stay in the body longer. Tirzepatide is the active ingredient in Mounjaro and Zepbound. Approval applies to a specific product, use, finished form, and current label. It does not apply to every item sold under the name tirzepatide.", "whatWeKnow": "Mounjaro's August 2026 label covers blood-sugar control in adults and children age 10 or older with type 2 diabetes. It also covers lower risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke in high-risk adults with type 2 diabetes. Cardiovascular death means death from heart or blood-vessel disease.\n\nZepbound's posted February 2026 label covers long-term weight reduction in defined adults and moderate-to-severe obstructive sleep apnea in adults with obesity. An August 26, 2026, FDA letter added cardiovascular trial information and a warning update. It did not add Mounjaro's heart-risk use to Zepbound.\n\nThe studies looked at specific groups of people for set periods. SURPASS-2 studied adults with type 2 diabetes for 40 weeks. SURMOUNT-1 studied adults with obesity, or overweight with a related condition, who did not have diabetes, for 72 weeks. These groups, comparisons, results, and study lengths limit each finding.", "whatWeDoNotKnow": "The evidence does not show that tirzepatide gives everyone the same result. It does not establish a universal “metabolic reset,” longer life, or better athletic performance. Evidence for approved medicines does not make compounded, counterfeit, or research-labeled products equivalent to those medicines.", "safetyBoundary": "Mounjaro's August 2026 label keeps the boxed warning about thyroid C-cell tumors seen in rats. The human risk is unknown. It also reports temporary worsening of diabetes-related eye disease when blood sugar improves quickly. Other product warnings and precautions still apply. This guide does not recommend a product or give dosing or dose-change instructions.", "claims": [ { "claim": "“Tirzepatide has established human outcome evidence for defined metabolic indications.”", "verdict": "Supported with scope", "explanation": "Posted product labels, an August 2026 FDA approval letter, and large randomized trials support specific blood-sugar, weight, and cardiovascular findings in defined populations. The cardiovascular risk-reduction use belongs to Mounjaro.", "category": "Clinical outcomes", "evidenceBasis": "Randomized human outcomes", "scope": "The labeled and trial populations, outcomes, comparators, and durations for Mounjaro and Zepbound. Mounjaro's heart-risk use was approved August 27, 2026.", "sourceUrls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s044s045lbl.pdf", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf", "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215866Orig1s044,215866Orig1s045ltr.pdf", "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/217806Orig1s041ltr.pdf", "https://pubmed.ncbi.nlm.nih.gov/35658024/", "https://pubmed.ncbi.nlm.nih.gov/34170647/" ] }, { "claim": "“Trial results prove tirzepatide works the same way for everyone and should be used indefinitely.”", "verdict": "Not established", "explanation": "Trials estimate effects for studied populations and durations. They do not establish an identical individual response or a universal treatment duration.", "category": "Clinical outcomes", "evidenceBasis": "Randomized human outcomes", "scope": "The defined populations and follow-up durations in SURMOUNT-1 and SURPASS-2.", "sourceUrls": [ "https://pubmed.ncbi.nlm.nih.gov/35658024/", "https://pubmed.ncbi.nlm.nih.gov/34170647/" ] }, { "claim": "“Compounded tirzepatide is equivalent to an approved product.”", "verdict": "Misleading", "explanation": "FDA does not review compounded drugs for safety, effectiveness, or quality before marketing, so evidence for an approved product cannot simply be transferred.", "category": "Product equivalence", "evidenceBasis": "Regulatory or product record", "scope": "Compounded or otherwise unapproved tirzepatide compared with approved Mounjaro or Zepbound.", "sourceUrls": [ "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss" ] } ], "sources": [ { "label": "MOUNJARO (tirzepatide) prescribing information, revised August 2026", "publisher": "U.S. Food and Drug Administration", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s044s045lbl.pdf", "kind": "Drug label", "accessedAt": "2026-10-12", "year": 2026 }, { "label": "ZEPBOUND (tirzepatide) prescribing information, revised February 2026", "publisher": "U.S. Food and Drug Administration", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf", "kind": "Drug label", "accessedAt": "2026-08-30", "year": 2026 }, { "label": "FDA approval letter: Mounjaro heart-risk indication, August 27, 2026", "publisher": "U.S. Food and Drug Administration", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215866Orig1s044,215866Orig1s045ltr.pdf", "kind": "FDA review", "accessedAt": "2026-08-30", "year": 2026 }, { "label": "FDA supplement letter: Zepbound cardiovascular-trial information, August 26, 2026", "publisher": "U.S. Food and Drug Administration", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/217806Orig1s041ltr.pdf", "kind": "FDA review", "accessedAt": "2026-08-30", "year": 2026 }, { "label": "FDA review: tirzepatide's 39-amino-acid structure", "publisher": "U.S. Food and Drug Administration", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000SumR.pdf", "kind": "FDA review", "accessedAt": "2026-08-30", "year": 2022 }, { "label": "Tirzepatide once weekly for the treatment of obesity", "publisher": "PubMed · New England Journal of Medicine", "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/", "kind": "Randomized trial", "accessedAt": "2026-08-30", "year": 2022 }, { "label": "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes", "publisher": "PubMed · New England Journal of Medicine", "url": "https://pubmed.ncbi.nlm.nih.gov/34170647/", "kind": "Randomized trial", "accessedAt": "2026-08-30", "year": 2021 }, { "label": "FDA’s concerns with unapproved GLP-1 drugs used for weight loss", "publisher": "U.S. Food and Drug Administration", "url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss", "kind": "Regulatory", "accessedAt": "2026-08-30", "year": 2026 } ], "aliases": [ "Mounjaro", "Zepbound", "GIP/GLP-1 agonist" ], "family": "Metabolic peptide medicines", "evidenceContext": "Approved human outcomes", "productContext": "Mounjaro and Zepbound are separate approved products. Their study results and labels do not apply to every compounded or research-labeled tirzepatide product.", "approvedProducts": [ "Mounjaro", "Zepbound" ], "productRecords": [ { "name": "Mounjaro", "formulation": "Injection", "route": "Subcutaneous", "indicationScope": "Blood-sugar control in defined type 2 diabetes populations. FDA approved a heart-risk reduction use for certain adults with type 2 diabetes on August 27, 2026.", "labelUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s044s045lbl.pdf", "labelRevision": "August 2026 published label" }, { "name": "Zepbound", "formulation": "Injection", "route": "Subcutaneous", "indicationScope": "Long-term weight management and moderate-to-severe obstructive sleep apnea in defined adults with obesity. An August 26, 2026 FDA supplement added cardiovascular-trial information, not a new use.", "labelUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf", "labelRevision": "February 2026 published label; August 26, 2026 supplement letter" } ], "indications": [ "Type 2 diabetes for labeled populations", "Lowering the risk of heart attack, stroke, or cardiovascular death in certain high-risk adults with type 2 diabetes under the August 27, 2026 Mounjaro approval", "Chronic weight management for labeled populations", "Moderate-to-severe obstructive sleep apnea in adults with obesity under the current Zepbound label" ], "reviewedAtISO": "2026-10-12", "reviewHistory": [ { "date": "2026-10-12", "note": "Updated the Mounjaro source to its August 2026 label and checked its approved uses and eye warning. Zepbound remains a separate product record." }, { "date": "2026-09-12", "note": "Checked the posted Mounjaro and Zepbound labels against their August supplement letters and clarified which product has each approved use." }, { "date": "2026-08-30", "note": "Updated Mounjaro and Zepbound label records, added the Mounjaro heart-risk approval and Zepbound supplement, and linked the FDA structure review." }, { "date": "2026-07-23", "note": "Expanded product, outcome, and unapproved-version boundaries." } ], "antiDoping": null, "antiDopingReview": { "status": "Not assessed", "detail": "This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.", "sourceUrl": null, "reviewedAtISO": "2026-07-23" }, "relatedSlugs": [ "semaglutide", "liraglutide", "retatrutide" ] } }